Kamm, Christian Philipp; El-Koussy, Marwan; Humpert, Sebastian; Findling, Oliver; von Bredow, Ferdinand; Burren, Yuliya; Schwegler, Guido; Schött, Dagmar; Donati, Filippo; Müller, Martin; Goebels, Norbert; Müller, Felix; Slotboom, Johannes; Tettenborn, Barbara; Kappos, Ludwig; Naegelin, Yvonne; Mattle, Heinrich Paul (2012). Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. Journal of neurology, 259(11), pp. 2401-13. Heidelberg: Springer-Verlag 10.1007/s00415-012-6513-7
|
Text
415_2012_Article_6513.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (256kB) | Preview |
Statins have anti-inflammatory and immunomodulatory properties in addition to lipid-lowering effects. The present study evaluated the effect of atorvastatin added to interferon beta-1b in multiple sclerosis (MS) in a multicenter, randomized, parallel-group, rater-blinded study performed in eight Swiss hospitals. Seventy-seven patients with relapsing-remitting MS started interferon beta-1b every other day. After 3 months, they were randomized 1:1 to receive atorvastatin 40 mg/day or not in addition to interferon beta-1b until month 15. The primary endpoint was the proportion of patients with new lesions on T2-weighted images at month 15 compared to baseline at month three. At study end, the proportion of patients with new lesions on T2-weighted images was equal in both groups (odds ratio 1.14; 95 % CI 0.36-3.56; p = 0.81). All predefined secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of new Gd-enhancing lesions on T1-weighted images, total brain volume, volume of grey matter, volume of white matter, EDSS, MSFC, relapse rate, time to first relapse, number of relapse-free patients and neutralizing antibodies did not show any significant differences (all p values >0.1). Transient elevations of liver enzymes were more frequent with atorvastatin (p = 0.02). In conclusion, atorvastatin 40 mg/day in addition to interferon beta-1b did not have a beneficial effect on relapsing-remitting MS compared to interferon beta-1b monotherapy over a 12-month period.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology 04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Institute of Diagnostic and Interventional Neuroradiology |
UniBE Contributor: |
Kamm, Christian Philipp, El-Koussy, Marwan, Findling, Oliver, Burren, Yuliya, Donati, Filippo, Slotboom, Johannes, Mattle, Heinrich |
ISSN: |
0340-5354 |
Publisher: |
Springer-Verlag |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:21 |
Last Modified: |
05 Dec 2022 14:06 |
Publisher DOI: |
10.1007/s00415-012-6513-7 |
PubMed ID: |
22569835 |
Web of Science ID: |
000310472100018 |
BORIS DOI: |
10.7892/boris.7039 |
URI: |
https://boris.unibe.ch/id/eprint/7039 (FactScience: 212188) |
Actions (login required)
 |
Edit item |